United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial

United Therapeutics Receives Regulatory Approval to Commence Phase I Study of
Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

HAIFA, Israel, April 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that following favorable preclinical studies,
United Therapeutics Corporation received approval to perform a human Phase I
study in Australia using Pluristem's PLacental eXpanded (PLX-PAD) cells in
patients diagnosed with Pulmonary Arterial Hypertension (PAH). On June 20,
2011 United Therapeutics and Pluristem entered into a licensing agreement
pursuant to which United Therapeutics will develop, market and sell
Pluristem's PLX-PAD cells for PAH.

PAH is characterized by abnormally high blood pressure in the arteries of the
lungs and leads to an increased workload on the right side of the heart.

United Therapeutics plans to conduct a single center, open-label,
dose-escalation study in patients diagnosed with PAH. The study will enroll up
to nine patients in three dosing levels with PLX-PAD cells administered
intravenously (IV). The primary endpoint of the study is to evaluate the
safety of PLX-PAD cells in a follow-up period of one year. Secondary efficacy
endpoints at six weeks post-treatment are designed to assess
cardio-respiratory function and include six-minute walk distance, cardiac
hemodynamic parameters via a right heart catheterization and echocardiogram
and pulmonary metabolism via a positron emission tomography (PET) scan. 

Zami Aberman, Chairman and Chief Executive Officer of Pluristem Therapeutics
stated, "We are very pleased with the progress of the project, moving our
partnership with United Therapeutics to the next step. The in-vitro and
pre-clinical development studies demonstrated that the administration of
PLX-PAD cells appears to be safe and potentially effective in animal models of
PAH. We are now looking forward to receiving clinical data from this trial in
evaluating the safety of our PLX-PAD cell in treating PAH patients."

Under the terms of Pluristem's licensing agreement with United Therapeutics
Corporation, United Therapeutics made an upfront payment of $7 million to
Pluristem. Pluristem is also eligible to receive regulatory milestone and
other payments totaling up to an additional $48 million with United
Therapeutics bearing all the costs of conducting all of the clinical trials
for the indication of PAH. The licensing agreement also provides that,
following commercialization, United Therapeutics will purchase the PLX-PAD
cell product from Pluristem at a specified margin over Pluristem's cost. In
addition, United Therapeutics will pay Pluristem specified royalties as a
percentage of its gross profits generated from the sale of the PLX-PAD cell
developed product.

Preclinical studies to evaluate the hemodynamic effects from the IV
administration of PLX-PAD cells in the monocrotaline (MCT) rat model of PAH
have been performed. These studies demonstrated that PLX-PAD cell treatment
can lead to improvements in right ventricular systolic pressure (RVSP)
compared to placebo-treated animals. Some treatment groups also demonstrated
an improvement in right ventricular hypertrophy (RVH) as compared to
placebo-treated animals.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the
development and commercialization of unique products to address the unmet
medical needs of patients with chronic and life-threatening diseases.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous
route.

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, we are using forward-looking
statements when (a) we discuss the planned study in patients diagnosed with
PAH, (b) we discuss the safety of PLX-PAD in treating PAH patients, and (c) we
discuss future milestone-based payments, royalty payments and purchase of
PLX-PAD cells for the indication of PAH, by United Therapeutics. These
forward-looking statements and their implications are based on the current
expectations of the management of Pluristem only, and are subject to a number
of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo